Last reviewed · How we verify

NCT07041944: HEMImprove-APP

HEMImprove 1.0 in Children and Adolescents With Unilateral Cerebral Palsy

Not yet recruiting NA Last updated 18 March 2026
What this trial tests

NA trial testing HEMImprove APP in Unilateral Cerebral Palsy in 36 participants. Not yet recruiting.

Timeline
1 March 2026
Primary endpoint
1 February 2027
1 December 2027

Quick facts

Lead sponsorUniversity of Castilla-La Mancha
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment36
Start date1 March 2026
Primary completion1 February 2027
Estimated completion1 December 2027

Drugs / interventions tested

Conditions studied

Sponsor

University of Castilla-La Mancha

Who can join

Adults 12 to 18, any sex, with Unilateral Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effectiveness and usability of HEMImprove 1.0, a gamified mobile application designed to improve upper limb motor function in adolescents with unilateral cerebral palsy. Participants will be randomly assigned to an intervention group using the app or a control group performing conventional home exercises. The intervention will last four weeks, with assessments before and after the intervention to measure motor function, motivation, and quality of life improvements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Unilateral Cerebral Palsy

Currently open trials in the same condition.

Other University of Castilla-La Mancha trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07041944.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing